Physician profile
Reshma Patel
NPI 1760693519
$8,093.75
in general payments reported to CMS, 2019-2025
41 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $431 · 2021: $1,005 · 2022: $894 · 2023: $1,652 · 2024: $2,089 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,539.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,257.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $754.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $730.49 | 2020-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $558.60 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $539.46 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $416.38 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.84 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $352.99 | 2020-2025 | Tymlos |
| Medtronic, INC. | $317.67 | 2021-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $312.68 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $262.76 | 2021-2024 | |
| Insulet Corporation | $228.95 | 2019-2025 | Omnipod |
| Abbvie INC. | $209.55 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $158.82 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $143.39 | 2020-2024 | Korlym |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $140.10 | 2020-2023 | Januvia, Steglujan, Steglatro |
| Sequel Med Tech, LLC | $117.77 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $116.03 | 2022-2024 | Strensiq |
| Madrigal Pharmaceuticals | $103.96 | 2025 | Rezdiffra |
| Cequr Corporation | $84.77 | 2022-2025 | Cequr Simplicity |
| Rhythm Pharmaceuticals, INC. | $82.28 | 2025 | Imcivree |
| Mannkind Corporation | $77.31 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $69.82 | 2025 | Yorvipath |
| Dexcom, INC. | $67.30 | 2021-2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $66.25 | 2024 | Ilet Bionic Pancreas |
| Recordati_rare_diseases_inc. | $50.12 | 2025 | Isturisa |
| Vivus LLC | $46.80 | 2021-2024 | Qsymia |
| Acella Pharmaceuticals, LLC | $45.34 | 2024-2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $45.15 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $43.93 | 2019 | |
| Ibsa Pharma INC. | $36.52 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.51 | 2021-2022 | |
| Inspire Medical Systems, INC. | $33.30 | 2025 | Inspire |
| Amphastar Pharmaceuticals, INC. | $28.31 | 2024 | |
| Neurocrine Biosciences, INC. | $26.66 | 2025 | |
| Kyowa Kirin, INC. | $24.67 | 2025 | |
| Chiesi USA, INC. | $22.96 | 2025 | Mycapssa |
| Astellas Pharma US INC | $22.91 | 2023 | Veozah |
| Echosens North America, INC. | $22.06 | 2024 | Fibroscan |
| Pfizer INC. | $17.41 | 2024 | |
| Ionis Pharmaceuticals, INC. | $15.46 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.